Drug developer ChanRx closes series A investment, hires CEO
Drug developer ChanRx has closed a series A round of investment that it will use to fund clinical trials of a pharmaceutical to treat atrial fibrillation. The Cleveland-area company, which was spun off from pharmaceutical testing firm ChanTest in 2006, didn’t specify the amount of the investment in a prepared statement. The round was led […]